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CASES PRESENTATION
In July of 2012, an Asian, 
52-year-old male smoker presented 
with a right cervical lymph node. 
A stage IV adenocarcinoma in the 
right lung; lymphangitis carcinoma-
tosis; mediastinal, cervical, and sus-
clavicular lymph nodes; and sacrum 
and hip bone osteoblastic metastases 
were diagnosed. Two-point mutations 
in exon 18 of the EGFR, p.I706T, and 
p.G719A were detected. Gefitinib treat-
ment started in August of 2012. After 3 
months, computed tomography -scan 
showed a partial response (Fig. 1).The 
clinical response was maintained under 
gefitinib treatment with 22 months of 
follow up.
The second patient was a 
Caucasian, 58-year-old female smoker, 
referred in February of 2013. A stage IV 
lung adenocarcinoma, in the lower right 
lobe, with mediastinal lymph nodes 
as well as cerebral and right adrenal 
gland metastases was diagnosed. Two-
point mutations in exon 18, p.E709K 
and p.G719A, were detected. Erlotinib 
treatment and whole brain radiotherapy 
began. After 2 months, the patient’s 
performance status improved and com-
puted tomography scan demonstrated 
a partial response on brain metastases 
and primary tumor. Then she presented 
with a progression of extracerebral 
metastases. Erlotinib was stopped. 
A chemotherapy combining cispla-
tin and pemetrexed was administered. 
In September of 2013, due to disease 
progression, carboplatin and paclitaxel 
were proposed. The patient presented 
a stable disease for 4 months and then 
progressed. She died 11 months after 
diagnosis of metastatic disease.
DISCUSSION
The clinical significance of 
EGFR complex mutations differs 
whether complex mutations include the 
most frequent mutations or not. Hata et 
al5 showed that tumours with complex 
mutations, including deletion of exon 19 
or L858R point mutation, had the same 
response rate to EGFR-TKI than those 
with the same mutations alone. Wu et al2 
showed that patients with rare and com-
plex mutations, compared with patients 
with classic or rare mutation alone or 
classic mutation with rare mutations, 
had a worse response rate to EGFR-
TKI (25% versus 74.8, 68.8, and 80%, 
respectively) and a poorer progression-
free survival (1.4 versus 11.9, 8.1, and 
8.0 months). Beau-Faller et al6 showed 
that EGFR-TKI efficacy was similar or 
slightly poorer in patients with complex 
mutations including p.G719X. Keam 
et al3 reported only two double muta-
tions in exon 18, including the G719A 
+ I706T, in a series of 306 patients. The 
overall survival of this patient, treated 
with erlotinib, was 53 months.3 This is 
the first description of the p.E709K + 
p.G719A mutation.
To date, the behavior of these 
NSCLCs with complex mutations are 
not completely understood. The report 
of these rare and complex mutations and 
their response to EGFR-TKI should be 
very useful for the constitution of well-
annotated databases and to improve the 
knowledge of their specific response to 
EGFR-TKI.
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FIGURE 1.  Computed tomography scan of chest of patient 1 (left) before treat-
ment and (right) after 3 months of gefitinib treatment.
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To the Editor:
In non–small-cell lung cancer 
(NSCLC) besides the common exons 
19 and 21 EGFR-activating muta-
tions (>90%), exon 18-point muta-
tions (mainly p.G719X) are rare (4%).1 
They are associated with a favorable 
response rate to EGFR tyrosine kinase 
inhibitors (EGFR-TKI),2,3 but are 
lower than common mutations.4 More 
than one mutation per sample repre-
sents complex mutations. Their clini-
cal significance is uncertain, because 
they are rare (3.4–6.9%).2,3 Here, we 
present two cases of NSCLC with rare 
complex mutation that respond differ-
ently to EGFR-TKI.
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